StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
REPL

Replimune Group, Inc.

REPL Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$11.91
+0.71 +6.34%

Key statistics

from XBRL data in SEC filings
Market cap
Revenue (TTM)
Net income (TTM)
EPS (TTM)
P/E ratio
Dividend yield
Free cash flow
Cash
Total assets
Gross margin
52-week range
$1.50 – $12.60

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Other events Jul 31, 2026 8-K Regulation FD disclosure Jul 30, 2026 10-K Fiscal year ended 2026-03-31 Jun 29, 2026 8-K Results of operations (earnings release) Jun 29, 2026 8-K Regulation FD disclosure Jun 26, 2026 8-K Regulation FD disclosure May 29, 2026 8-K Regulation FD disclosure; Other events Apr 13, 2026 10-Q Quarter ended 2025-12-31 Feb 3, 2026 8-K Entered a material agreement; Results of operations (earnings release); Took on a direct financial obligation Feb 3, 2026 8-K Regulation FD disclosure Jan 12, 2026 8-K Results of operations (earnings release) Nov 6, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Other events Oct 20, 2025 8-K Regulation FD disclosure; Other events Sep 18, 2025 8-K Shareholder vote results; Regulation FD disclosure Sep 4, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Regulation FD disclosure; Other events Jul 22, 2025 8-K Regulation FD disclosure Jun 24, 2025 10-K Fiscal year ended 2025-03-31 May 22, 2025 8-K Results of operations (earnings release) May 22, 2025 8-K Entered a material agreement; Director or officer change Mar 7, 2025 10-Q Quarter ended 2024-12-31 Feb 12, 2025 8-K Results of operations (earnings release) Feb 12, 2025 8-K Other events Jan 22, 2025 8-K/A Other events Dec 4, 2024 8-K Other events Nov 27, 2024 8-K Other events Nov 26, 2024 8-K Regulation FD disclosure; Other events Nov 21, 2024 10-Q Quarter ended 2024-09-30 Nov 12, 2024 8-K Results of operations (earnings release) Nov 12, 2024 8-K Shareholder vote results Sep 5, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Jun 13, 2024 8-K Regulation FD disclosure; Other events Jun 6, 2024 8-K Other events Jun 3, 2024 10-K Fiscal year ended 2024-03-31 May 16, 2024 8-K Results of operations (earnings release) May 16, 2024 8-K Director or officer change; Other events Mar 26, 2024